Krystal Biotech (NASDAQ:KRYS) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Krystal Biotech from hold to buy, adding to a generally bullish analyst backdrop. The stock now carries a Moderate Buy consensus with an average target price of $324.11.
• Krystal Biotech reported strong quarterly results, posting $1.83 EPS versus expectations of $1.45 and revenue of $116.36 million, above estimates. The company also showed solid profitability with a 19.25% return on equity and 53.92% net margin.
• The stock was trading near its 12-month high, opening at $305.71 after a 3% gain, while insiders have recently sold shares and institutional ownership remains high at 86.29%.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

KRYS has been the subject of a number of other research reports. The Goldman Sachs Group lifted their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a "buy" rating in a research report on Friday, January 30th. Weiss Ratings raised Krystal Biotech from a "hold (c+)" rating to a "buy (b-)" rating in a report on Thursday, April 9th. Wolfe Research initiated coverage on Krystal Biotech in a research report on Friday, March 27th. They set a "peer perform" rating on the stock. HC Wainwright reaffirmed a "buy" rating and set a $310.00 price objective on shares of Krystal Biotech in a research report on Monday, May 4th. Finally, Guggenheim increased their target price on Krystal Biotech from $224.00 to $284.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $324.11.

Krystal Biotech Trading Up 3.0%

Shares of NASDAQ:KRYS opened at $305.71 on Friday. The stock has a fifty day simple moving average of $263.06 and a two-hundred day simple moving average of $248.61. The stock has a market capitalization of $9.01 billion, a price-to-earnings ratio of 40.87 and a beta of 0.50. Krystal Biotech has a 12-month low of $122.80 and a 12-month high of $306.10.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.45 by $0.38. The business had revenue of $116.36 million during the quarter, compared to analysts' expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. As a group, equities research analysts predict that Krystal Biotech will post 7.98 EPS for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 12,500 shares of the firm's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the transaction, the chief accounting officer directly owned 19,318 shares in the company, valued at $5,257,200.52. This trade represents a 39.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Dino A. Rossi sold 18,950 shares of the firm's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total value of $4,953,719.50. Following the transaction, the director owned 78,691 shares in the company, valued at $20,570,614.31. The trade was a 19.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 129,164 shares of company stock valued at $34,538,578. Company insiders own 13.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KRYS. Bessemer Group Inc. increased its holdings in shares of Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company's stock valued at $26,000 after acquiring an additional 77 shares during the period. Sound Income Strategies LLC grew its stake in Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company's stock worth $34,000 after buying an additional 127 shares during the last quarter. Greenline Wealth Management LLC purchased a new position in Krystal Biotech during the 4th quarter worth $34,000. Danske Bank A S purchased a new position in Krystal Biotech during the 3rd quarter worth $35,000. Finally, UMB Bank n.a. grew its stake in Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after buying an additional 37 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.